Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:RVPH NASDAQ:TARA NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$11.60+14.2%$7.53$3.39▼$16.00$133.63M0.88211,948 shs362,485 shsRVPHReviva Pharmaceuticals$0.44-1.7%$0.44$0.30▼$4.28$30.38M-0.042.20 million shs625,103 shsTARAProtara Therapeutics$3.15-0.6%$3.13$1.60▼$10.48$122.31M1.52164,637 shs101,581 shsZNTLZentalis Pharmaceuticals$1.75-1.1%$1.49$1.01▼$5.44$127.68M1.76812,105 shs422,761 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+14.17%+24.87%+39.59%+182.93%+54.26%RVPHReviva Pharmaceuticals-1.75%-2.44%-2.44%-46.56%-64.88%TARAProtara Therapeutics-0.63%+0.96%+1.29%-5.69%+63.21%ZNTLZentalis Pharmaceuticals-1.13%+3.55%+26.81%+15.13%-46.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$11.60+14.2%$7.53$3.39▼$16.00$133.63M0.88211,948 shs362,485 shsRVPHReviva Pharmaceuticals$0.44-1.7%$0.44$0.30▼$4.28$30.38M-0.042.20 million shs625,103 shsTARAProtara Therapeutics$3.15-0.6%$3.13$1.60▼$10.48$122.31M1.52164,637 shs101,581 shsZNTLZentalis Pharmaceuticals$1.75-1.1%$1.49$1.01▼$5.44$127.68M1.76812,105 shs422,761 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+14.17%+24.87%+39.59%+182.93%+54.26%RVPHReviva Pharmaceuticals-1.75%-2.44%-2.44%-46.56%-64.88%TARAProtara Therapeutics-0.63%+0.96%+1.29%-5.69%+63.21%ZNTLZentalis Pharmaceuticals-1.13%+3.55%+26.81%+15.13%-46.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00158.62% UpsideRVPHReviva Pharmaceuticals 3.14Buy$5.201,084.51% UpsideTARAProtara Therapeutics 3.17Buy$19.60522.22% UpsideZNTLZentalis Pharmaceuticals 2.67Moderate Buy$8.20368.57% UpsideCurrent Analyst Ratings BreakdownLatest RVPH, AVTX, ZNTL, and TARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVTXAvalo TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy8/18/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00 ➝ $3.008/18/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/15/2025RVPHReviva PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/15/2025AVTXAvalo TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight8/15/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $2.008/7/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ZNTLZentalis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.006/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K346.68N/AN/A$12.80 per share0.91RVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/AZNTLZentalis Pharmaceuticals$67.43M1.87N/AN/A$4.73 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%11/6/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)TARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%11/11/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$165.84M-$2.26N/AN/AN/AN/A-51.62%-40.28%11/11/2025 (Estimated)Latest RVPH, AVTX, ZNTL, and TARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/A8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/A8/7/2025Q2 2025AVTXAvalo Therapeutics-$1.43-$1.92-$0.49-$1.92N/AN/A8/6/2025Q2 2025ZNTLZentalis Pharmaceuticals-$0.56-$0.37+$0.19-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A12.4412.44RVPHReviva PharmaceuticalsN/A0.900.90TARAProtara TherapeuticsN/A12.8112.82ZNTLZentalis PharmaceuticalsN/A7.997.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%RVPHReviva Pharmaceuticals63.18%TARAProtara Therapeutics38.13%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%RVPHReviva Pharmaceuticals27.18%TARAProtara Therapeutics8.40%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4013.15 million12.75 millionNot OptionableRVPHReviva Pharmaceuticals568.00 million49.52 millionOptionableTARAProtara Therapeutics3038.58 million35.34 millionOptionableZNTLZentalis Pharmaceuticals16072.14 million70.76 millionOptionableRVPH, AVTX, ZNTL, and TARA HeadlinesRecent News About These CompaniesNuveen LLC Takes $807,000 Position in Zentalis Pharmaceuticals, Inc. $ZNTLSeptember 4 at 3:25 AM | marketbeat.comZentalis Pharmaceuticals Grants Stock Options to New Employees as Part of Inducement PlanSeptember 2, 2025 | quiverquant.comQZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comZentalis Pharmaceuticals Announces New Chief Legal OfficerAugust 26, 2025 | msn.comZentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate SecretaryAugust 26, 2025 | globenewswire.comGuggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)August 19, 2025 | theglobeandmail.comZentalis Pharmaceuticals (ZNTL) Gets a Buy from TD CowenAugust 18, 2025 | theglobeandmail.comZentalis (ZNTL) Q2 Loss Narrows 70%August 18, 2025 | theglobeandmail.comLeerink Partnrs Has Pessimistic View of ZNTL Q3 EarningsAugust 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZNTL Q3 EarningsAugust 11, 2025 | marketbeat.comHC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"August 10, 2025 | marketbeat.comWall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to HoldAugust 10, 2025 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings ResultsAugust 9, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CAAugust 9, 2025 | marketbeat.comZentalis price target lowered to $5 from $6 at Wells FargoAugust 8, 2025 | msn.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & CompanyAugust 8, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.August 7, 2025 | marketbeat.comZentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational ProgressAugust 6, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVPH, AVTX, ZNTL, and TARA Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$11.60 +1.44 (+14.17%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.27 +0.67 (+5.78%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Reviva Pharmaceuticals NASDAQ:RVPH$0.44 -0.01 (-1.75%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.45 +0.01 (+1.59%) As of 09/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Protara Therapeutics NASDAQ:TARA$3.15 -0.02 (-0.63%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.17 +0.02 (+0.60%) As of 09/5/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.75 -0.02 (-1.13%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.71 -0.04 (-2.29%) As of 09/5/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
